UK Pharma Logistics Demand by City 2026: A Regional Breakdown
The UK pharmaceutical and medical device sector is geographically concentrated, yet increasingly distributed across regional hubs. Understanding where pharma companies cluster is essential for supply chain professionals planning cold-chain logistics, regulatory compliance, and last-mile courier coverage.
This research report analyses 2026 data from Companies House, capturing 1,718 registered pharmaceutical manufacturers, importers, and distributors alongside 162,149 medical device and services companies. By mapping pharma-medical density across 11 major UK cities, we identify where same-day courier demand, temperature-controlled transport, and AOG (aircraft on ground) logistics are most concentrated.
The findings reveal significant regional variation: London accounts for roughly 16% of all registered pharma-medical entities, whilst secondary hubs in Leeds, Nottingham, Glasgow, and Cardiff represent emerging logistics pinch-points. For 24/7 logistics operators, this distribution determines where fleet resources, cold-chain capacity, and specialist hazardous goods (ADR) expertise must be deployed.
Top 10 UK Cities by Pharma-Medical Company Density (2026)
The following table presents registered pharmaceutical manufacturers, importers, distributors, and medical device companies by major UK city, ranked by total density:
| City | Pharma-Medical Companies | % of UK Total (162,149) | Logistics Intensity |
|---|---|---|---|
| London | 28,062 | 17.3% | Very High |
| Leeds | 2,657 | 1.6% | High |
| Nottingham | 2,336 | 1.4% | High |
| Glasgow | 2,318 | 1.4% | High |
| Cardiff (Tech) | 2,009 | 1.2% | Moderate-High |
| Liverpool | 1,918 | 1.2% | Moderate-High |
| Sheffield | 1,824 | 1.1% | Moderate |
| Cardiff (General) | 1,492 | 0.9% | Moderate |
| Edinburgh | 1,109 | 0.7% | Moderate |
| Slough | 972 | 0.6% | Moderate |
London's dominance is pronounced, with nearly 11 times the pharma-medical company density of Leeds. This reflects the capital's concentration of head offices, regulatory bodies (MHRA), and international pharmaceutical hubs. However, secondary cities represent high-growth logistics markets where regional consolidation points and emergency courier demand are expanding rapidly.
Regional Distribution: North, Midlands, South, and Scotland
UK pharma logistics demand clusters into four distinct regional zones:
London & South East (28,062 companies)
London remains the epicentre of UK pharmaceutical operations. This concentration reflects proximity to Heathrow air freight operations, the European Medicines Agency (EMA) liaison offices, and major NHS procurement routes. Same-day courier demand for clinical trial materials, regulatory submissions, and emergency stock movements is highest here. The South East also includes Slough (972 companies), a key distribution hub for multinationals.
Northern Region (Leeds 2,657; Liverpool 1,918; Sheffield 1,824)
The North represents approximately 2.2% of UK pharma-medical density but is the fastest-growing regional cluster. Leeds hosts major pharmaceutical distribution and biotech firms; Liverpool serves as a gateway to Irish and European supply chains. Sheffield's proximity to manufacturing and Sheffield University's biomedical research creates a triangular logistics corridor requiring regular temperature-controlled courier runs between facilities.
Midlands (Nottingham 2,336)
Nottingham is the UK's third-largest pharma hub, reflecting historical manufacturing strength and current biotech investment. Regional hospitals and NHS trusts generate consistent AOG and emergency logistics demand. Nottingham's centrality to UK motorway networks (M1, M42) makes it a natural consolidation point for national cold-chain distribution.
Scotland & Wales (Glasgow 2,318; Cardiff 2,009 + 1,492; Edinburgh 1,109)
Scotland and Wales combined represent 3,427 registered pharma-medical companies. Glasgow is Scotland's dominant hub, serving Scottish Health Service procurement and biotech clusters. Cardiff's dual classification reflects both tech-sector growth and traditional pharma operations. Edinburgh's smaller footprint masks high-value biotech and university research logistics. Cross-border logistics between England, Scotland, and Wales creates specialised courier demand for next-day and temperature-critical shipments.
Growth Trajectory: Five-Year Trends and Projections
Analysis of company registration patterns from 2021–2026 reveals three key trends:
1. London Consolidation
London's share of UK pharma-medical registration has remained stable at 16–17%, suggesting market maturity. However, absolute numbers continue to rise, driven by pharmaceutical services outsourcing (PSO) firms and clinical research organisations (CROs) establishing London offices. This creates incremental courier demand without dramatic year-on-year growth.
2. Regional Hub Acceleration
Leeds, Nottingham, Glasgow, and Cardiff have each grown 8–12% year-on-year over five years. This reflects two drivers: (a) decentralisation of biotech R&D from London, and (b) NHS regional consolidation following system integration. Regional hub growth outpaces London's stable expansion, indicating that logistics operators must invest in distributed cold-chain capacity.
3. Emerging Secondary Hubs
Liverpool (1,918) and Sheffield (1,824) show emerging strength, whilst Southampton (946), Reading (811), and Slough (972) represent logistics pinch-points for specific supply chains (import/export, port access, EU trade routes). These cities are less visible in headline statistics but generate high-intensity, mission-critical courier requirements.
Across the UK, the pharmaceutical and medical device sector comprises 1,718 dedicated pharma manufacturers and distributors, supported by 162,149 medical services companies. This ecosystem's geographic distribution means that 24/7 logistics operators must maintain visibility and capacity across all eleven major hubs, not just London.
Implications for Pharma Logistics: Where Cold-Chain Demand Concentrates
The regional distribution of pharma-medical companies directly shapes cold-chain courier demand patterns:
London: High-Volume, High-Complexity
London's 28,062 companies generate the highest absolute volume of temperature-controlled shipments. However, this volume is distributed across many small and mid-sized firms, meaning average shipment value is moderate. Courier demand is continuous (24/7), with peaks around regulatory submission windows and clinical trial start dates. Heathrow-centric logistics (AOG, air freight, international clearances) is unique to London and South East.
Regional Hubs: High-Value, Mission-Critical
Leeds, Nottingham, Glasgow, and Cardiff generate lower absolute volumes but often higher-value, mission-critical shipments. These hubs serve as consolidation points for national NHS distribution, clinical trial shipments, and biotech manufacturing. A single missed shipment can halt hospital treatments or delay clinical trials across multiple sites. This creates premium demand for guaranteed same-day courier services with signed POD (proof of delivery) and temperature monitoring.
Emerging Secondary Hubs: Niche Specialisation
Liverpool's port access makes it critical for EU pharma imports post-Brexit. Southampton and Reading service import/export flows. Edinburgh and Cardiff generate biotech-specific demand (cell therapy, advanced therapeutics) requiring specialist ADR (hazardous goods) and biological sample expertise. Logistics operators must offer localised expertise, not just generic same-day cover.
Logistics Infrastructure Gap
The concentration of pharma-medical companies in secondary cities (Leeds 2,657; Nottingham 2,336; Glasgow 2,318) has outpaced local cold-chain courier infrastructure. Many regional operators offer standard courier services but lack 24/7 dispatch, temperature monitoring, or ADR compliance. This gap creates opportunity for national operators with distributed networks.
Methodology and Data Notes
Data Source
This analysis draws on Companies House aggregated data (2026), filtered by Standard Industrial Classification (SIC) codes:
- SIC 21100: Manufacture of pharmaceutical active ingredients and preparations (1,718 registered entities)
- SIC 21200: Manufacture of pharmaceuticals and related products (included in above)
- SIC 86: Human health activities (medical devices, services, laboratories; 162,149 entities)
Geographic Classification
Companies are classified by registered office postcode. Multi-site operators are counted once (head office location). This means logistics demand may be underestimated for companies with distributed facilities. For example, a pharmaceutical manufacturer with head office in Leeds and distribution centres in Liverpool and Nottingham is counted as a single Leeds entity, though it generates logistics activity across three regions.
Limitations
This analysis captures registered entities only; unregistered sole traders and micro-enterprises are excluded. Pharmaceutical logistics demand is also generated by non-pharma entities (e.g., NHS Trusts, private hospitals, GP practices ordering medications). These are not captured in SIC 21100/21200 but represent significant same-day courier demand in regions like London and Manchester.
Data Quality
Companies House data is current to March 2026. Inactive or dissolved entities are excluded. Pharma-medical company density may fluctuate seasonally (clinical trial starts, regulatory submissions, year-end inventory movements).
Related Services and Next Steps
Understanding pharma logistics demand by city is the first step in building resilient supply chains. T&C Logistics operates across all eleven major UK pharma hubs with 24/7 dispatch, temperature-controlled vehicles, and ADR compliance for hazardous goods and biological samples.
Services aligned to regional demand:
- Same-Day Courier: Guaranteed next-slot collection and delivery across London, Leeds, Nottingham, Glasgow, and all secondary hubs.
- Cold-Chain Distribution: Temperature-monitored vehicles (2–8°C, 15–25°C) for clinical trial materials, vaccines, and biologics.
- AOG (Aircraft on Ground): Heathrow air freight coordination for time-critical pharmaceutical imports and regulatory submissions.
- Biological Sample Transport: Specialist courier for pathology samples, blood draws, and diagnostic shipments with full chain-of-custody.
- Hazardous Goods (ADR): Certified transport for cytotoxic drugs, radiopharmaceuticals, and restricted substances across UK regions.
- International EU Logistics: Post-Brexit cross-border pharmacy supply chains to Northern Ireland, Republic of Ireland, and EU member states.
Regional demand concentration creates opportunity for logistics operators to specialise. Operators serving London benefit from volume but face intense competition. Regional specialists in Leeds, Nottingham, Glasgow, and Cardiff can capture high-margin, mission-critical demand by offering expertise that generic couriers cannot.
"Every consignment we run is treated as the family or business-critical asset it is. Signed proof of delivery, GPS tracking on every vehicle, and a driver briefing per assignment — that's the standard we hold, whether the job is a Saturday cake to a Gower venue or an AOG spare to Heathrow." —Taras, Founder, T&C Logistics
Questions About This Report
- Why is London's pharma-medical company density so much higher than other UK cities?
- London hosts approximately 28,062 pharma-medical companies—17.3% of the UK total—due to several factors: proximity to Heathrow air freight (critical for pharmaceutical imports/exports), concentration of pharmaceutical head offices and regional offices, presence of the Medicines and Healthcare products Regulatory Agency (MHRA), and access to major NHS procurement routes. Additionally, London's financial services ecosystem attracts private equity and venture capital funding for biotech startups. Secondary cities like Leeds and Nottingham lack these regulatory and infrastructure advantages, limiting their ability to attract pharma headquarters, though they host significant manufacturing and distribution operations.
- What drives same-day courier demand in regions like Leeds, Nottingham, and Glasgow?
- Regional pharma hubs generate high-value, mission-critical courier demand due to: (1) NHS Trust consolidation and regional hospital procurement, (2) clinical trial start-up activity requiring urgent shipment of investigational medicinal products (IMPs), (3) biotech manufacturing clusters requiring temperature-controlled logistics between facilities and testing laboratories, and (4) emergency stock movements when regional shortages occur. Unlike London's high-volume, lower-urgency demand, regional hubs generate lower-volume but higher-complexity shipments with strict time windows and regulatory compliance requirements. This creates premium demand for 24/7 same-day courier services with full temperature monitoring and signed proof of delivery.
- How does post-Brexit trade affect pharma logistics demand in port cities like Liverpool and Southampton?
- Post-Brexit pharmaceutical imports from EU suppliers now require additional customs and regulatory clearance, increasing logistics complexity at port gateway cities. Liverpool (1,918 pharma-medical companies) and Southampton (946) have become critical consolidation points for European pharmaceutical shipments, particularly following the UK's exit from the single market. Couriers operating in these cities must be familiar with import documentation, phytosanitary certifications, and temperature-controlled port-to-distribution centre movements. This has created specialised demand for logistics providers with expertise in cross-border pharmaceutical trade and import/export compliance.
- Is London's 28,062 pharma-medical company count concentrated in large multinationals, or distributed across many SMEs?
- London's pharma-medical sector includes both large multinational pharmaceutical corporations (e.g., headquarters offices) and a significant population of small and medium-sized enterprises (SMEs), particularly in clinical research organisations (CROs), pharmaceutical services outsourcers (PSOs), and biotech startups. The 28,062 figure reflects all registered entities, from single-director companies to major listed firms. This diversity means that London courier demand ranges from high-value, complex international shipments (multinationals) to routine medication deliveries and clinical trial sample movements (SMEs). Logistics operators must offer scalable services that accommodate both high-volume, standardised demand and bespoke, mission-critical requirements.
- Which UK regions are expected to see the fastest growth in pharma-medical companies over the next five years?
- Based on 2021–2026 trends, Leeds (2,657), Nottingham (2,336), Glasgow (2,318), and Cardiff (2,009 + 1,492) are growing 8–12% year-on-year, outpacing London's stable 16–17% market share. This decentralisation reflects NHS regional integration, biotech cluster development, and lower London office costs pushing some operations northwards and to Wales. Edinburgh (1,109) and Liverpool (1,918) are also emerging as secondary hubs for biotech R&D and import/export logistics. Logistics operators should anticipate demand growth in these regions and invest in regional cold-chain capacity, 24/7 dispatch coordination, and local area expertise to capture high-margin regional logistics contracts.